XML 116 R28.htm IDEA: XBRL DOCUMENT
v3.25.1

INCOME TAXES (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2024
Income Tax Disclosure [Abstract] |
SCHEDULE OF INCOME TAX PROVISION | The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2024 and 2023 is as follows: PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 SCHEDULE OF INCOME TAX PROVISION
US |  | June 30, 2024 |  |  | June 30, 2023 |
|  | Year Ended |
US |  | June 30, 2024 |  |  | June 30, 2023 |
Loss before Income taxes |  | $ | (1,874,914 | ) |  | $ | (2,790,407 | )
Taxes under statutory US tax rates |  | $ | (393,732 | ) |  | $ | (585,986 | )
Increase (decrease) in valuation allowance |  |  | 306,682 |  |  |  | 556,521 |
Foreign tax rate differential |  |  | (55,358 | ) |  |  | (60,316 | )
Prior period adjustment |  |  | 76,194 |  |  |  | 81,599 |
Other |  |  | 66,214 |  |  |  | 8,182 |
Income tax (expense) benefit |  | $ | - |  |  | $ | - |
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES | SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES
|  | June 30, 2024 |  |  | June 30, 2023 |
|  | Year Ended |
|  | June 30, 2024 |  |  | June 30, 2023 |
Deferred tax assets |  |  |  |  |  |  |  |
Warrant Derivative Liability |  | $ | 513,071 |  |  | $ | 579,544 |
Accrued Expenses |  |  | 559,723 |  |  |  | 478,273 |
Prepaid Investor Services |  |  | 551,796 |  |  |  | 575,021 |
Non-cash interest |  |  | 817,536 |  |  |  | 758,797 |
Intangibles (Intellectual Property and Patent Cost) |  |  | 351,144 |  |  |  | 321,557 |
Deferred Rent |  |  | 4,492 |  |  |  | 4,550 |
Formation Expense |  |  | 6,553 |  |  |  | 6,553 |
Net Operating Loss carryforward |  |  | 9,075,029 |  |  |  | 8,910,874 |
Gain on extinguishment of debt |  |  | 97,992 |  |  |  | 47,393 |
Stock Based Compensation |  |  | 84,028 |  |  |  | 84,028 |
Total Deferred tax assets |  | $ | 12,061,364 |  |  | $ | 11,766,590 |
Deferred tax liabilities |  |  |  |  |  |  |  |
Research and Development |  | $ | (170,435 | ) |  | $ | (202,568 | )
Foreign Exchange Loss (OCI) |  |  | (39,379 | ) |  |  | (39,379 | )
Capital Raising Costs |  |  | (389,258 | ) |  |  | (369,033 | )
Total deferred tax liabilities |  | $ | (599,072 | ) |  | $ | (610,980 | )
Net deferred tax assets |  | $ | 11,462,292 |  |  | $ | 11,155,610 |
Valuation allowance |  |  | (11,462,292 | ) |  |  | (11,155,610 | )
Net deferred tax assets |  | $ | - |  |  | $ | - |
SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT | The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio. SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT
Historical per share data – (Pre- Split basis) |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |
Net loss available to Common Stockholders |  | $ | 2,013,488 |  |  | $ | 3,126,839 |
Basic and diluted weighted average shares outstanding |  |  | 85,045,339 |  |  |  | 1,738,802 |
Basic and diluted net loss per share |  | $ | 0.02 |  |  | $ | 1.80 |
The assumption inherent in the table below is a reverse split of 1:100,000.
Historical per share data – (Post- Split basis) |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |
Net loss available to Common Stockholders |  | $ | 2,013,488 |  |  | $ | 3,126,839 |
Basic and diluted weighted average shares outstanding |  |  | 850 |  |  |  | 17 |
Basic and diluted net loss per share |  | $ | 2,368.81 |  |  | $ | 183,931.71 |
The table below shows the loss per share effect of reverse stock splits at 1:10,000, 1:50,000 and 1:100,000:
|  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |  |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |  |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |
Split Ratio |  | 1:10,000 |  |  | 1:50,000 |  |  | 1:100,000 |
|  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |  |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |  |  | Year Ended June 30, 2024 |  |  | Year Ended June 30, 2023 |
Net losses available to common stockholders |  | $ | 2,013,488 |  |  | $ | 3,126,839 |  |  | $ | 2,013,488 |  |  | $ | 3,126,839 |  |  | $ | 2,013,488 |  |  | $ | 3,126,839 |
Weighted Average Shares Outstanding |  |  | 8,505 |  |  |  | 174 |  |  |  | 1,701 |  |  |  | 35 |  |  |  | 850 |  |  |  | 17 |
Loss per share |  | $ | 236.74 |  |  | $ | 17,970 |  |  | $ | 1,183.71 |  |  | $ | 89,338.26 |  |  | $ | 2,368.81 |  |  | $ | 183,931.71 |

X
- Definition Schedule of Loss Per Share Basis of Reverse Stock Split [Table Text Block] + References No definition available. + Details
Name: | PPCB_ScheduleOfLossPerShareBasisOfReverseStockSplitTableTextBlock
Namespace Prefix: | PPCB_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details
Name: | us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details
Name: | us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration